Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aclaris Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Aclaris Therapeutics, Inc.’s stock price such as:

• Aclaris Therapeutics, Inc.’s current stock price and volume
• Why Aclaris Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ACRS from analysts
• ACRS’s stock price momentum as measured by its relative strength

About Aclaris Therapeutics, Inc. (ACRS)

Before we jump into Aclaris Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Want to learn more about Aclaris Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc.’s Stock Price as of Market Close

As of May 13, 2026, 9:30 AM, CST, Aclaris Therapeutics, Inc.’s stock price was $4.830.

Aclaris Therapeutics, Inc. is down 1.02% from its previous closing price of $4.880.

During the last market session, Aclaris Therapeutics, Inc.’s stock traded between $4.830 and $4.830. Currently, there are approximately 128.81 million shares outstanding for Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Aclaris Therapeutics, Inc. Stock Price History

Aclaris Therapeutics, Inc.’s (ACRS) price is currently up 11.29% so far this month.

During the month of May, Aclaris Therapeutics, Inc.’s stock price has reached a high of $5.120 and a low of $4.260.

Over the last year, Aclaris Therapeutics, Inc. has hit prices as high as $5.120 and as low as $1.160. Year to date, Aclaris Therapeutics, Inc.’s stock is up 60.47%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aclaris Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 12, 2026, there were 2 analysts who downgraded Aclaris Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Aclaris Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aclaris Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Aclaris Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aclaris Therapeutics, Inc. (ACRS) by visiting AAII Stock Evaluator.

Relative Price Strength of Aclaris Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 12, 2026, Aclaris Therapeutics, Inc. has a weighted four-quarter relative price strength of 33.62%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Aclaris Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aclaris Therapeutics, Inc. Stock Price: Bottom Line

As of May 13, 2026, Aclaris Therapeutics, Inc.’s stock price is $4.830, which is down 1.02% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aclaris Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.